LMAP-12 TUMOR TREATING FIELDS (TTFIELDS) REAL-WORLD EXPERIENCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OVERALL SURVIVAL

Abstract BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression by a multi-modal mechanism of action. TTFields therapy is FDA-approved for newly diagnosed glioblastoma (ndGBM) based on results from the randomized, phase 3 EF-14 study (NCT00916409). We assessed the overall survival (OS) benefit of adding TTFields therapy to standard of care (SOC) in ndGBM, as well as the relationship between OS and time using the device. METHODS A systematic literature review (PubMed, Embase, and Cochrane Library) identified single-cohort and comparative clinical studies that assessed survival in patients with ndGBM who received TTFields therapy. Inter-study heterogeneity was quantified using the Higgins I2 statistic and Cochran Q test. A distribution-free random-effects method was used to pool survival curves. RESULTS Nine studies were identified that evaluated survival with TTFields therapy in ndGBM. Of these, 7 studies (1430 patients) that compared TTFields therapy with SOC to SOC alone, were included in the pooled analysis for OS. The pooled data showed significantly longer OS with TTFields therapy/SOC versus SOC alone (HR: 0.63; 95% CI, 0.53-0.75; P